Category Archives: Biochemistry

With already 2900 people dead from the flu, we need a better vaccine – MSUToday

The CDC estimates that at least 6.4 million people have caught the flu, resulting in 55,000 hospitalizations and 2,900 deaths already this season. Though the flu vaccine can reduce the chances of infection at best, it's only 40% to 60% effective, which is why we need a better vaccine.

Michigan State University researchers are working on this global health problem and have data that show how cellular RNA levels change following infection or vaccination. RNA stands for ribonucleic acid, which is a long, single-stranded chain of cells that processes protein and carries genetic information of many viruses, including influenza. This discovery could help make future flu vaccines work better or even aid in the design of a universal vaccine.

Understanding these differences could help us identify new targets for building better vaccines as well as help us figure out better ways to treat the disease, said George Mias, assistant professor of biochemistry and molecular biology and chief of the Systems Biology Division at the Institute for Quantitative Health Science and Engineering at MSU.

Mias and his co-authors reanalyzed data from 18 previously published studies where scientists had taken blood samples from flu patients and vaccine recipients and studied those samples for gene expression. Gene expression can be measured by looking for the levels of RNA in cells. When a gene is expressed in a cell it means the DNA has been used to produce RNA for this gene. The gene expression in cells can change in response to stimuli, including disease.

The motivation for combining the different datasets is that typically the smaller datasets will be underpowered statistically to detect significant differences, Mias said. By combining multiple studies, were increasing our power and ability to detect gene expression differences between the variables that were interested in.

The researchers found 978 genes with changed expression for flu infection and flu vaccination. Roughly a third of those genes, 334, overlapped while about two-thirds, 644, were unique to either flu infection or flu vaccination.

The distinct genes were involved in different processes in the body. Several genes that were expressed differently in flu infection, for example, are involved in the bodys defensive mechanisms. On the flip side, genes exclusively expressed in vaccination were involved in antigen processing, which stimulates the bodys immune response.

The investigators also found 907 genes related to age and 48 related to sex that affect disease/vaccine gene expression changes. Understanding these differences could help scientists in their quest to develop a universal vaccine.

We especially need to find something that works across ages better, Mias said.

At present, the CDC recommends a high-dose vaccine for people over the age of 65 because their immune systems need more stimulation in order to create the necessary antibodies to protect them from flu viruses.

Mias and his co-authors hope their results will serve as a starting point for future studies by providing gene targets that could be further explored through animal models or human research using newer RNA-sequencing technology.

We found things that are specific to the flu or to the vaccine, so we need to ask, What are the effects of those genes? Mias said. For instance, if the vaccine is activating additional genes and pathways that the disease itself is not activating, we should be asking, Are they relevant and could they be linked to any side effects? Those are questions that deserve to be answered.

The paper was published in the journal Frontiers in Immunology. Co-authors are Gustavo de los Campos, professor of epidemiology and biostatistics at MSU, and Lavida Rogers, former MSU graduate student.

(Note for media: Please include a link to the original paper in online coverage: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02616/full)

Written by Nancy Averett

Original post:
With already 2900 people dead from the flu, we need a better vaccine - MSUToday

NMSU students win awards for research at National Diversity in STEM Conference – New Mexico State University NewsCenter

Date: 01/06/2020Writer: Amanda Adame, 575-646-7953, aadame4@nmsu.edu Facebook Twitter LinkedIn Google+ Pinterest

Four New Mexico State University students in the College of Arts and Sciences were honored at the Society for the Advancement of Chicanos/Hispanics and Native Americans in Science (SACNAS) awards at The 2019 National Diversity in STEM Conference in Honolulu in November. The awards recognize the next generation of underrepresented researchers and Science, Technology, Engineering and Math (STEM) leaders while also giving visibility to their research and schools.

The student researchers represented areas of study from sociology to biology and chemistry and biochemistry as well as conservation ecology.

We are proud to see our students presenting their research at the largest multidisciplinary and multicultural STEM event in the country, said Enrico Pontelli, dean of the College of Arts and Sciences. SACNAS has a solid history of serving the purpose of engaging and encouraging underrepresented students in the STEM fields.

Daniel Aguirre, who is conducting research in NMSUs Department of Chemistry and Biochemistry, presented a poster in the chemistry category titled, In-Silico Dual Specificity Protein Phosphatase Differentiation Via Molecular Dynamic Simulations. His presentation included research about Dual Specificity Protein Phosphatases and if they play a role in the development of cancer, obesity and autoimmunity.

Isabella Terrazas, who is studying microbiology, presented about her research Cortical Granule Motility in Response to Hormone Stimulation during Sea Star Meiosis. She is studying how fertilization and proper development is required for sperm to bind. This activation of Rho, G proteins and actin, cell division plays a role in promoting translocation of cortical granules (CGs) to the cell surface.

Valerie Brewer, who is studying conservation ecology, presented her research Effects of Urbanization on Extra-Pair Paternity in the Song Sparrow. She explored how urbanization can affect the behavior of free-living animals. Preliminary results suggested that there are higher rates of extrapair offspring and nests in rural areas compared to urban.

Riva Silver, an unclassified student, presented her sociological research Exploring the Pathway Model Connecting Water and Education in West Texas Colonias Using Quasi-Youth Participatory Action Research; A Mixed Methods Approach. Through youth participatory action research, the study explored the connection between water infrastructure and high school graduation rates in unincorporated communities in rural areas that dont have access to city water and sewer services. The results suggest improved water infrastructure increases quality of life and education, which promotes higher high school graduation rates.

The students were among 82 graduate and undergraduate underrepresented groups in sciences. These awards also help encourage students to continue pursing STEM fields. The organization serves a community of over 20,000 supporters, more than 6,000 members and more than 115 student and professional chapters throughout the United States and Puerto Rico.

The SACNAS National Diversity in STEM Conference partners with institutions by providing a venue where students and professionals are able to enhance their science communication skills. As a multidisciplinary scientific society, the opportunity to present research to a general scientific audience fosters skills needed to not only build public support for science but also ensure that science is accessible to everyone. Through the awards, we recognize and celebrate presenters that make STEM inclusive, said Sonia Zrate, SACNAS President.

To learn more about SACNAS and the presentations by NMSU students visit sacnas.org.

Read more here:
NMSU students win awards for research at National Diversity in STEM Conference - New Mexico State University NewsCenter

Researchers study the effects of antidepressants to identify the least harmful drugs – News-Medical.net

About one in ten women in Qubec will suffer from depression during pregnancy. Without treatment, the illness carries risks for both mother and child. Yet antidepressants are not without consequences for fetal development. The team of professor Cathy Vaillancourt at the Institut National de la Recherche Scientifique (INRS) is studying the effects of these drugs in order to identify the least harmful ones.

Professor Vaillancourt, in collaboration with the teams of Professors J. Thomas Sanderson and Nicolas Doucet of the INRS, has just modeled for the first time the interaction of commonly used antidepressants with estrogen, and more specifically with the enzyme that synthesizes the estrogen: aromatase. It is an important contribution, since estrogen production is essential to the development of the fetus and to the mother's physiological adaptation during pregnancy. The results of their study were recently published in The Journal of Steroid Biochemistry and Molecular Biology.

Prescribing antidepressants for pregnant women is controversial. Studies show that, when administered to mothers during pregnancy, some of these treatments are associated with a risk of heart and lung malformations in newborns. Others are thought to result in impaired cognitive development, including autism, in children.

The harmful effects of antidepressants are thought to be due to their interaction with certain key hormones. Most antidepressants prescribed to pregnant women target serotonin, a hormone produced both in the brain and, as shown by Professor Vaillancourt's team in 2017, in the placenta. This is the family of antidepressants called selective serotonin reuptake inhibitors (SSRIs) such as Zoloft, Celexa or Prozac. However, estrogen would also be targeted by these treatments.

We wanted to see how the antidepressants that have been developed to block the serotonin transporter also affect aromatase. Using molecular models, we found that all the antidepressants we analyzed seemed to be able to bind directly to the enzyme and regulate its activity. This remains to be confirmed and the precise mechanism needs to be further investigated."

Cathy Vaillancourt, lead author of the study

Her doctoral student tested the effect of different types of antidepressants on placenta samples collected after delivery. "The antidepressants we chose to test are those most commonly prescribed in pregnant women, namely sertraline (Zoloft), venlafaxine (Effexor), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa)," says Andre-Anne Hudon Thibeault "By comparing different doses and molecules, we were able to uncover some of their specificities."

By observing the effects of antidepressants on the placenta's hormonal system, the team can determine in advance if there will be a risk for the fetus. "Fetal development is strongly linked to the placenta. Every healthy fetus has a healthy placenta," maintains Vaillancourt.

Not all types of antidepressants have these harmful effects. Not all pharmacological molecules have the same hormonal affinity. "Depending on its form, a molecule may not interact the same way with estrogen and may therefore be less harmful to the developing fetus," asserts Professor Vaillancourt, who specializes in the involvement of maternal exposure to environmental and drugs factors in the endocrinology of the human placenta.

It's more a matter of the pharmacological molecule being administered and the dosage. "By testing several types of antidepressants at varying doses, our work will contribute to better choices regarding the type of antidepressant and the dose prescribed for pregnant women, while minimizing the side effects on the course of pregnancy and on fetal development," says Andre-Anne Hudon Thibeault, primary author and recent PhD graduate of INRS.

Discontinuing medication isn't always advisable. Depression can have serious consequences if left untreated. "Depression is one of the leading risk factors for suicide in pregnant women," says Vaillancourt. "Some studies suggest that depression can also compromise fetal development, due in part to poor lifestyle habits."

At the same time, Professor Vaillancourt is collaborating with a team of researchers in Vancouver who are studying a cohort of pregnant women and following their children over the long term. "This will give us a nice map of the various effects in women and the consequences for children's heart and brain development," says Vaillancourt. "We're still in the early stages of the project, but I'm confident that some antidepressants are safer and others can be developed for use during pregnancy."

Source:

Journal reference:

Thibeault, A-A. H., et al. (2019) Serotonin and serotonin reuptake inhibitors alter placental aromatase. The Journal of Steroid Biochemistry and Molecular Biology. doi.org/10.1016/j.jsbmb.2019.105470.

Read the original here:
Researchers study the effects of antidepressants to identify the least harmful drugs - News-Medical.net

Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO – Yahoo Finance

LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO.

Dr. Jennifer Buell, President & COO of Agenus

"Jen's tenure with Agenus, her exceptional leadership and cultural attributes, and her deep understanding of our science and operations makes her the top candidate for this newly created position," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. He added, "I am very excited to partner with Jen as we set to realize Agenus' vision of defeating cancer in the coming years."

After her tenure at Harvard Clinical Research Institute, Dr. Buell rejoined Agenus in 2013 as the Head of Global R&D operations. She was subsequently appointed as Chief Communications and External Affairs Officer, and then, to the position of Chief Operating Officer.

Dr. Buell brings over 20 years of biopharmaceutical industry experience and knowledge. Her efforts in the rapid advancement of discovery candidates through development has resulted in Agenus' record of advancing 13 I-O candidates to the clinic in the past four years. Her experience also includes extensive communication with internal and external constituencies, regulators, investors, and collaborators. Dr. Buell's previous operational and research experience include her tenures at Bristol-Myers Squibb and Harvard Clinical Research Institute. Dr. Buell obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' clinical development plans and timelines, the vision of defeating cancer in the coming years, and the expected contributions of Dr. Buell. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Story continues

See the article here:
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO - Yahoo Finance

Persistent TB infection of macrophages puts the brakes on immune engines, study shows – News-Medical.net

Scientists from Trinity College Dublin have discovered both how TB puts the brakes on our immune engines and how we can kick-start those engines back into gear - providing hope that improved treatment options could soon be on the horizon.

Although ancient, TB is still the world's deadliest infectious disease. While it is rampant in Africa, the growing problem of antibiotic resistance is posing a significant threat worldwide.

Part of TB's success as a pathogen is because of its ability to infect the cells of our immune system, which are normally tasked with responding to the infection. It infects our lung macrophage cells and then manipulates them to its benefit - creating a safe home for it to hide out unperturbed, sometimes for years.

As part of an SFI-funded Starting Investigator Research Grant, Frederick Sheedy, Ussher Assistant Professor in the School of Biochemistry and Immunology at Trinity, mentored by St James' Hospital TB specialist, Professor Joseph Keane, has been examining how these lung macrophage immune cells fuel the fight against infection.

The work has been at the forefront of showing how the simple sugar glucose is used to promote the macrophages anti-bacterial activities.

In surprising results, published this week in leading international journal Cell Reports, Dr Emer Hackett (a PhD candidate in Professor Sheedy's group) found that persistent infection of these macrophages with TB puts the brakes on the glucose-fuelled engine. This essentially shuts down our natural response to infection, which allows the bacteria to hide out unperturbed.

Specifically, Dr Hackett found a small RNA molecule (which comprises tiny pieces of genetic information) which the bacteria promotes and which targets key enzymes that act as pumps in our immune engines to commit glucose to promote the anti-bacterial response.

When the bacteria promotes this small RNA molecule, which is termed microRNA-21, these enzyme pumps are removed from the engine and glucose is not used in the same way. This then allows the bacteria to escape and thrive.

Although this newly identified pathway is corrupted by the bacteria, the study also yielded some hope for the future.

Professor Sheedy explained:

We found that when TB-infected cells are treated with a key 'Interferon gamma protein signal' which is normally produced following vaccination, they will remove this microRNA to effectively relieve the brake and restore our normal immune response.

What is particularly promising from a societal impact perspective is that as well as increasing our knowledge of how TB corrupts our normal immune response to infection, our identification of the microRNA-21 means that scientists should be able to develop improved immunotherapies or vaccine strategies to help in the fight against TB infection."

Source:

Journal reference:

Hackett, E.E., et al. (2020) Mycobacterium tuberculosis Limits Host Glycolysis and IL-1 by Restriction of PFK-M via MicroRNA-21. Cell Reports. doi.org/10.1016/j.celrep.2019.12.015.

See the rest here:
Persistent TB infection of macrophages puts the brakes on immune engines, study shows - News-Medical.net

Global Chitin and Chitin Derivatives Market Industry Trends and Forecast to 2025 | Yunzhou Biochemistry Co., Advanced Biopolymers AS, Biophrame…

The global chitin and chitin derivatives market report provides with CAGR value fluctuation during the forecast period of 2018-2025 for the market. The numerical data is backed up by statistical tools such as SWOT analysis, porters five forces analysis and else. The readers will find this report very helpful in understanding the chitin and chitin derivatives market in depth. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and porters five forces analysis.

Get Sample Analysis of This Market Information:https://databridgemarketresearch.com/request-a-sample/?dbmr=global-chitin-chitin-derivatives-market

Global Chitin and Chitin Derivatives Market accounted for USD 2.3 billion in 2017 and is projected to grow at a CAGR of 15.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2015, 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Chitin is obtained from shrimp, crab and lobster waste. Chitin has wide range of application in food and beverages, agrochemical industry, healthcare industry among others. Some of the major players in Global Chitin and Chitin Derivatives Market include:-

Yunzhou Biochemistry Co.

Advanced Biopolymers AS

Biophrame Technologies

United Chitotechnologies Inc.

Koyo World (Hong Kong) Co. Ltd.

Dainichiseika Color & Chemicals Mfg. Co. Ltd.

Agratech LLC.

Kraeber & Co. GmbH

Foodchem International Corporation

FMC Corporation

GTC Bio Corporation

Panvo Organics Pvt., Ltd.

KitoZyme S.A.

Xianju Tengwang Chitosan Factory

Golden-Shell Pharmaceutical Co.

PT Biotech Surindo

TaizhouCandorly Sea Biochemical & Health Products Co. Lt

Heppe Medical Chitosan GmbH

Sonat Co

Kunpoong Bio Co. Ltd

The Global Chitin and Chitin Derivatives Market are fragmented with the presence of a large number of players across different regions. These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Get TOC For Full Analysis Of Report:https://databridgemarketresearch.com/toc/?dbmr=global-chitin-chitin-derivatives-market

Market Drivers:

Waste and water treatment to offer significant growth opportunities for chitin market in the coming years

Increasing need of chitin in biomedical and biopharmaceutical industry.

Easy raw material availability

Market Restraint:

As it is derived from natural resources such as crabs, extinction of the species may raise environmental concerns.

Synopsis of the report:

1. Major players and brands

2. Drivers and restrains of the market

3. Industry Chain Suppliers of Chitin and Chitin Derivatives Market with Contact Information

4. Historical, current and projected market size in terms of volume and value

5. In-depth market segmentation

6. Competitive landscape

Market Segmentation:

on the basis of Derivative Type

Glucosamine,

Chitosan,

Others

On the basis of end user:

Food and Beverages,

Agrochemical,

Healthcare,

Cosmetics and Toiletries,

Waste and Water Treatment,

Others

On the basis of geography:

North America,

South America,

Europe,

Asia-Pacific,

Middle East & Africa.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Want Full Report? Enquire Here:https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-chitin-chitin-derivatives-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-281

Email: sopan.geda[emailprotected]

Go here to read the rest:
Global Chitin and Chitin Derivatives Market Industry Trends and Forecast to 2025 | Yunzhou Biochemistry Co., Advanced Biopolymers AS, Biophrame...

New provost will be a "student of Yale" – Yale Alumni Magazine

Mark Zurolo 01MFA View full image

Since arriving at Yale in 1995, Scott Strobel, now the Henry Ford II Professor of Molecular Biophysics and Biochemistry, has taken on a series of administrative roles: chair of his department; vice president for West Campus planning and program development; deputy provost for teaching and learning; and vice provost for science initiatives. Now, in his highest-profile assignment yet, Strobel has been tapped by President Peter Salovey 86PhD as Yales new provostthe universitys chief academic and budgetary officersucceeding Ben Polak, who is returning to the economics faculty.

Strobel grew up around science, playing in the lab of his father, a plant pathologist at Montana State University. (I was probably doing stuff you shouldnt really let a kid do in a lab, he says.) He obtained his undergraduate degree in biochemistry from Brigham Young University, earned his doctorate at Caltech, and did postdoctoral work at the University of Colorado.

The other major influence in his early years: membership in the Bozeman Hawkers, his high schools speech and debate team. Being on that team transformed who I was and what I realized I could do, Strobel says. Its where I became comfortable in front of a classroom and in public settings.

Strobels dedication to the classroom is evidenced by the several Yale and national awards he has won for teaching and mentoring. He also oversaw the creation of Yales Poorvu Center for Teaching and Learning, accessible to everyone in Sterling Library. Its glass walls, he notes, are a reminder that teaching is a public experience that should be shared in a community of scholars.

When Strobel first moved into administration, he continued teaching his award-winning Rainforest Expedition and Laboratory course, a spring-term and summer undergraduate biology class that took Strobel and his students to the South American rain forest to analyze microorganisms they found in plant tissues. Eventually, he stopped teaching to focus on administrative responsibilities, including transforming a vast former pharmaceutical research complex into Yales West Campus, which now houses seven interdisciplinary institutes as well as the School of Nursing. (In his off hours, he has turned his wood-turning hobby into a business: he makes bowls and pens with wood salvaged from trees on the Yale campus that have been removed because of overgrowth, disease, or construction.)

When his appointment was announced in November, Strobel set a goal of meeting with every dean and speaking to as many faculty members as possible to better understand the totality of the university, pledging to be a student of Yale as well as one of its leaders. And hes not willing to give up teaching entirely: he plans to guest-lecture next spring in Donald Engelmans Biology, the World and Us, an introductory science course for nonscience majors.

Being offered a position at Yale 25 years ago was a dream come true, Strobel says. I hoped it would be an institution where my two passions of teaching and research were fully integrated. I am deeply grateful to President Salovey for the trust he is placing in me to help shape Yales future, and to determine how best to use its resources to help improve the world.

Read the original post:
New provost will be a "student of Yale" - Yale Alumni Magazine

Meet Silicon Valley’s own Willy Wonka and his chocolate-making robot – Palo Alto Online

Only in Silicon Valley does a longtime tech startup founder find a second career in a chocolate-making robot.

Nate Saal studied molecular biophysics and biochemistry at Yale University after graduating from Palo Alto High School in 1990. After returning to Palo Alto, he quickly shifted from science to the internet, founding what he says was the first web-based software updating service in 1996. He went on to start more technology companies and later worked for CNET and Cisco.

But these days, he's immersed in chocolate -- specifically, chocolate made by a countertop device that he created called CocoTerra. The sleek white device, which looks like a large, futuristic coffee maker, uses algorithms, hardware and a smartphone app to transform cocoa nibs, milk powder, cocoa powder and sugar into chocolate in about two hours.

Saal has high hopes for the machine, which has yet to be released. In the age of automation, where robots are making pizza and ramen and delivering our food, he sees CocoTerra as doing something different: using technology to deepen rather than disrupt people's connection to how their food is made.

"We're not trying to slap technology for technology's sake on top of that to abstract it away, to take creativity away," he said. "We're trying to actually create a whole new category of people who can now make chocolate."

While Saal's professional career has focused on technology, he has always filled his weekends with homegrown food experiments, like keeping bees and growing grapes and olives to make wine and olive oil from scratch. He's fascinated by the "deep science" of these activities.

Making chocolate, however, was not in his repertoire. It wasn't until he took his brother-in-law, who works in the coffee business, to a chocolate tasting several years ago, and a conversation about the similarities between the two industries got him thinking. His brother hypothesized that home coffee machines have allowed more people to understand and appreciate coffee in a way that chocolate hasn't experienced. People did make chocolate at home, but it was a lengthy process that required having several expensive appliances, he found.

"There's a bread machine, an ice cream maker and a juicer and a pasta maker and a tea brewer and a coffee maker -- every major food category has a home appliance. What I discovered very quickly was there is no such thing (for chocolate)," Saal said.

He educated himself by going to chocolate-making classes, including a boot camp at Madre Chocolate in Hawaii. Back in Palo Alto, he and a team got to work designing a device that could combine all steps in the chocolate-making process -- grinding, refining, conching, tempering and molding -- in one machine. It typically grinds the single-origin cocoa nibs for about half an hour, using stainless steel balls, then refines the cocoa butter, sugar and milk powder. Conching is the "slow manipulation or agitation of chocolate at elevated temperatures to help drive off some undesired flavors," said Chief Operating Officer Karen Alter. Named for conch shell-shaped equipment, this is part of the process is often on display during chocolate factory tours, she said, with large vats that have paddles slowly moving liquid chocolate.

The next step, tempering, involves cooling the ingredients to a specific temperature that will create a specific structure of seed crystal in the cocoa butter molecules, Saal enthusiastically explained. The crystals solidify, creating shiny, hard chocolate. A patented centrifuge inside the machine cools and spins the chocolate to remove bubbles.

The final result is a ring-shaped, half-pound mold of chocolate, rather than the traditional rectangular bar.

On the back end, technology allows a level of customization that CocoTerra's creators hope will make the device as appealing for experts as for novices. A cloud-based recipe system, accessible online or via an app, guides you from start to finish in a recipe. People can either default to CocoTerra's recipes, such as 62% dark chocolate or milk chocolate with almonds, or customize them, from level of sweetness and creaminess, to added flavors and ingredients, to the tempering temperature. People can easily control for allergies or dietary restrictions.

CocoTerra will sell the base ingredients directly to customers, focusing on fair trade, ethically grown nibs, or people can use their own. Those who are advanced enough to roast and shell their own cacao beans could still do that, put them into the machine and then create their own recipes.

Producing quality chocolate in two hours is "jaw-dropping" to many in the chocolate industry, Saal said.

"I thought they were totally crazy when I first talked to them on the phone," John Scharffenberger told CNBC. Scharffenberger, who co-founded Scharffen Berger in San Francisco in 1997 before small batch, artisan chocolate was a thing, is now a CocoTerra investor and calls it "a natural extension of the craft chocolate movement."

The company won't disclose a price for the machine, which they claim is the world's first tabletop chocolate maker. CocoTerra has raised more than $2 million in investments and is now focused on a larger round to fund the release of the device.

"This is about the evolution of technology to make chocolate. But it's also making it accessible," Saal said. "We're bringing that to people by using smart mechanical engineering and software to make it accessible so that you can actually now focus on things like the flavor and recipe and the look and the design and the craft of it."

The rest is here:
Meet Silicon Valley's own Willy Wonka and his chocolate-making robot - Palo Alto Online

Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Re | COPD – Dove Medical Press

Olaf Holz,1,* David S DeLuca,2,* Stefan Roepcke,3 Thomas Illig,2 Klaus M Weinberger,46 Christian Schudt,7 Jens M Hohlfeld1,2

1Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research, Hannover, Germany; 2Hannover Medical School, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research, Hannover, Germany; 3Department of Biomarker Development, Takeda Pharmaceuticals International GmbH, Zrich, Switzerland; 4Biocrates Life Sciences AG, Innsbruck, Austria; 5Research Group for Clinical Bioinformatics, Private University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria; 6sAnalytiCo Ltd, Belfast, Ireland; 7Department of Biochemistry, ALTANA, Konstanz, Germany

*These authors contributed equally to this work

Correspondence: Olaf HolzDepartment of Clinical Airway Research, Fraunhofer ITEM, Hannover 30625, GermanyTel +49-511-5350-8141Fax +49-511-5350-8250Email olaf.holz@item.fraunhofer.de

Purpose: There is an ongoing demand for easily accessible biomarkers that reflect the physiological and pathophysiological mechanisms of COPD. To test if an exercise challenge could help to identify clinically relevant metabolic biomarkers in COPD.Patients and Methods: We performed two constant-load exercise challenges separated by 4 weeks including smokers with COPD (n=23/19) and sex- and age-matched healthy smokers (n=23/20). Two hours after a standardized meal venous blood samples were obtained before, 5 mins after the start, at the end of submaximal exercise, and following a recovery of 20 mins. Data analysis was performed using mixed- effects model, with the metabolite level as a function of disease, time point and interaction terms and using each individuals resting level as reference.Results: Exercise duration was longer in healthy smokers but lactate levels were comparable between groups at all four time points. Glucose levels were increased in COPD. Glutamine was lower, while glutamate and arginine were higher in COPD. Branched-chain amino acids showed a stronger decline during exercise in healthy smokers. Carnitine and the acyl-carnitines C16 and C18:1 were increased in COPD. These metabolite levels and changes were reproducible in the second challenge.Conclusion: Higher serum glucose, evidence for impaired utilization of amino acids during exercise and a shift of energy metabolism to enhanced consumption of lipids could be early signs for a developing metabolic syndrome in COPD. In COPD patients, deviations of energy and nitrogen metabolism are amplified by an exercise challenge.

Keywords: targeted metabolomics, biomarker, airway inflammation

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Follow this link:
Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Re | COPD - Dove Medical Press

Study focuses on key structure of C. difficle bacteria that could lead to future treatments – Business Standard

You are here Home Video Gallery Study focuses on key structure of C. difficle bacteria that could lead to future treatments Study focuses on key structure of C. difficle bacteria that could lead to future treatments

New Delhi, Jan 06 (ANI): Researchers have identified the structure of the most lethal toxin produced by certain strains of Clostridium difficile bacteria, a potentially deadly infection associated with the use of antibiotics. The finding of the study was published in the journal of Proceedings of the National Academy of Sciences.

Researchers at the University of Maryland School of Medicine and their colleagues used cryo-electron microscopy, X-ray crystallography and other biophysical methods to identify the microscopic structures of the bacteria. The researchers mapped out the delivery and binding components of the toxin, which could pave the way for new drugs to neutralize it.

"We identified two structures that help explain the molecular underpinnings of C. difficile toxicity," said study co-author David Weber, Ph.D., a Professor of Biochemistry and Molecular Biology and Director of the Center for Biomolecular Therapeutics at UMSOM.

"These structures will be important for targeting th

JANUARY 06, 2020, MONDAY

New Delhi, Jan 06 (ANI): Several politicians arrived to Jawaharlal ...

JANUARY 06, 2020, MONDAY

New Delhi, Jan 06 (ANI): Students held protest outside Delhi Police ...

JANUARY 06, 2020, MONDAY

New Delhi, Jan 06 (ANI): Congress general secretary Priyanka Gandhi ...

JANUARY 06, 2020, MONDAY

New Delhi, Jan 06 (ANI): Deputy Commissioner of Police (Southwest) ...

JANUARY 06, 2020, MONDAY

New Delhi, Jan 6 (ANI): Delhi Police conducted flag march inside JNU ...

';if(neverShowNotificaitonCookie==''||neverShowNotificaitonCookie=='undefined'||neverShowNotificaitonCookie==null){var lastReminderCookie=getCookie('_ler'+loginParamObj.uId);if((lastReminderCookie=="")||(lastReminderCookie=="undefined")||(lastReminderCookie==null)){$('body').prepend(notificationBox);}else{if(lastReminderCookie

Original post:
Study focuses on key structure of C. difficle bacteria that could lead to future treatments - Business Standard